Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantation

This publication has 50 references indexed in Scilit:

• Mammalian target of rapamycin inhibition as therapy for hematologic malignancies
  Cancer, 2004
• Sirolimus and tacrolimus allow engraftment of haploidentical and other alternative donor stem cells after non-myeloablative conditioning
  Transplantation and Cellular Therapy, 2004
• Thrombotic microangiopathy associated with combined sirolimus and tacrolimus immunosuppression after intestinal transplantation
  Transplantation, 2004
• Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation
  Oncogene, 2003
• Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation
  Blood, 2003
• A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients
  Transplantation, 2003
• Rapamycin is an effective inhibitor of human renal cancer metastasis11See Editorial by Sukhatme and Strom, p. 1160.
  Kidney International, 2003
• Rapamycin impairs antigen uptake of human dendritic cells1
  Transplantation, 2003
• Successful treatment of tacrolimus-associated thrombotic microangiopathy with sirolimus conversion and plasma exchange
  Clinical Nephrology, 2002
• Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia
  New England Journal of Medicine, 1986